Mevion Medical Systems

Mevion Medical Systems is a United States medical-technology company focused on proton therapy for cancer treatment. The company says it was incorporated in 2004 with the goal of reducing the size and cost of proton therapy technology and making the treatment more accessible. Its work centers on compact proton accelerators and clinical systems intended for cancer centers, clinicians, and patients. Mevion’s principal product family is the MEVION S250 Series. The company describes the series as a smaller clinical system designed to combine treatment performance with lower system complexity, reduced capital and operating costs, and comparatively rapid deployment. The range includes the MEVION S250-FIT, MEVION S250i, MEVION S250, and the multi-room MEVION S250mx. The S250i incorporates HYPERSCAN pencil beam scanning technology. Mevion positions its products as solutions for cancer centers of different sizes, emphasizing clinical performance, uptime, throughput, and the economics of operating a proton therapy service. The company’s history page traces a development partnership with the Massachusetts Institute of Technology in 2006, focused on a high-field magnet intended to reduce accelerator size. Mevion says it completed development of the smallest proton accelerator for proton therapy in 2010, and that its MEVION S250 received US FDA clearance in 2012 as the world’s first compact proton therapy system. The first patient treatment on an S250 took place at Siteman Cancer Center in 2013. The company subsequently announced further product development, installations, and international activity. Mevion presents itself as an international supplier and support partner for proton therapy centers. Its website reports systems installed and treating patients, highlights customer support, and promotes the S250 Series’ small footprint and operating economics. Current homepage announcements include the first clinical treatment on the MEVION S250-FIT, a selection of the system for a project in Türkiye, and a partnership with Tam Anh General Hospital to bring proton therapy to Vietnam. The supplied sources identify Lawrence Yuan Tian as chairman, Tina Tianning Yu as chief executive officer and president, and Curt Kienast as chief operating officer. They do not establish the company’s ownership, parent company, or listing status.

Proton therapy was proposed as a cancer treatment in 1946 and first used clinically in 1954, according to Mevion’s company history. The first hospital-based proton therapy treatment center opened in 1990, but the company’s account notes that the technology’s size and cost limited its wider adoption. Mevion was incorporated in 2004 with the stated aim of reducing the size and cost of proton therapy technology and making the treatment more accessible. In 2006, Mevion entered a development partnership with the Massachusetts Institute of Technology to develop a high-field magnet intended to reduce the size of a proton accelerator. Mevion reports completing development of the smallest proton accelerator for proton therapy in 2010. In 2012, the MEVION S250 received US FDA clearance. Mevion describes it as the world’s first compact proton therapy system. The first patient was treated on an S250 at Siteman Cancer Center in St. Louis in 2013. Mevion announced development of its HYPERSCAN pencil beam scanning technology in 2014. In 2015, the company reported S250 clinical treatment at another NCI Comprehensive Cancer Center and at a physician-owned proton therapy center in Jacksonville, Florida, as well as the announcement of its first S250 Series installation in Europe. That year it also announced an investment round and a joint venture to develop proton centers in China, and introduced the S250i with HYPERSCAN and the multi-room S250mx. The supplied history-page excerpt ends during its entry for 2016, so further historical details are not included here. The current product portfolio presented on Mevion’s website is the S250 Series, including the S250-FIT, S250i, S250, and S250mx. The company describes the systems as compact options for cancer centers, emphasizing efficient beam transport, patient throughput, reduced system complexity, and lower capital and operating costs. The website also reports current international activity, including a system selection in Türkiye, a partnership to bring proton therapy to Vietnam, and the first clinical treatment on the S250-FIT. The company’s leadership page names Lawrence Yuan Tian as chairman, Tina Tianning Yu as CEO and president, and Curt Kienast as COO. Available evidence does not specify the company’s founders, owners, parent company, or listing status.

• 2015

  S250i and S250mx introduced; European installation and China joint venture announced

• 2014

  HYPERSCAN pencil beam scanning technology announced

• 2013

  First patient treated on the MEVION S250 at Siteman Cancer Center

• 2012

  MEVION S250 receives US FDA clearance

• 2010

  Mevion completes development of a compact proton accelerator

• 2006

  Development partnership with MIT begins

• 2004

  Mevion incorporated

• 1990

  First hospital-based proton therapy treatment center opens

• 1954

  Proton therapy first used clinically

• 1946

  Proton therapy proposed for cancer treatment

A provider of compact proton therapy systems, emphasizing clinical performance, smaller footprint, uptime, lower costs, and deployment for cancer centers.

• MEVION S250-FIT Proton Therapy System

  A proton therapy system in Mevion’s S250 Series.

• MEVION S250i Proton Therapy System

  An S250 Series system incorporating HYPERSCAN pencil beam scanning technology.

• MEVION S250 Proton Therapy System

  Mevion’s compact proton therapy system that received US FDA clearance in 2012.

• MEVION S250mx Multi-Room Proton Therapy System

  A multi-room proton therapy system in the S250 family.

• HYPERSCAN

  Mevion’s pencil beam scanning technology.

• 2020-10-19

  Mevion partners with Hermes Advanced Therapy Systems for distribution in Taiwan and Southeast Asia[6]Mevion与Hermes Advanced Therapy Systems合作在台湾及东南亚分销biospace.com

  Reported: 2020-10-19

  Mevion Medical Systems announced a partnership agreement with Hermes Advanced Therapy Systems Corp. to distribute the MEVION S250i Proton Therapy System in Taiwan and Southeast Asia, including Malaysia, Thailand and Singapore.

1. 1Mevion Medical Systems | Proton Therapymevion.com
2. 2History – Mevion Medical Systems | Proton Therapymevion.com
3. 3Products – Mevion Medical Systems | Proton Therapymevion.com
4. 4About-Mevion – Mevion Medical Systems | Proton Therapymevion.com
5. 5Mevion Medical Systems (United States)wikidata.org
6. 6Mevion与Hermes Advanced Therapy Systems合作在台湾及东南亚分销biospace.com
7. 7Mevion partners with Hermes Advanced Therapy Systems to expand reach in Asiaen.antaranews.com